Literature DB >> 1826276

Outpatient microsurgical reversal of tubal sterilization by a combined approach of laparoscopy and minilaparotomy.

P D Silva1, A M Schaper, J K Meisch, C W Schauberger.   

Abstract

A prospective study of 17 cases of microsurgical reversal of tubal sterilization by a combined approach of laparoscopy and minilaparotomy was performed. Inclusion criteria included age less than 43; weight less than ideal body weight plus 20%; documentation of ovulation; 2 cm of proximal oviduct on hysterosalpingography; and a normal semen analysis or postcoital test. A comparison group of the 5 cases of sterilization reversal performed by a standard inpatient technique during the same period was analyzed. The study technique was performed on an outpatient basis in 15 of the 17 cases, 12 patients (71%) conceived 13 intrauterine pregnancies, one ectopic pregnancy occurred, and total patient costs and time until return to work were significantly less with the study versus standard technique.

Entities:  

Keywords:  Acceptor Characteristics; Acceptors; Americas; Control Groups; Delivery Of Health Care; Demographic Factors; Developed Countries; Endoscopy; Examinations And Diagnoses; Family Planning; Family Planning Programs; Female Sterilization; Fertility; Fertility Measurements; Health; Health Facilities; Laparoscopy; Minilaparotomy; North America; Northern America; Outpatient Clinic; Parity; Physical Examinations And Diagnoses; Population; Population Dynamics; Prospective Studies; Research Methodology; Reversible Sterilization; Sterilization Reversal; Sterilization, Sexual; Studies; Tubal Ligation; Tubal Occlusion; Tubal Reanastomosis; United States; Wisconsin

Mesh:

Year:  1991        PMID: 1826276     DOI: 10.1016/s0015-0282(16)54232-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

1.  The suprapubic cruciate incision for laparoscopic-assisted microceliotomy.

Authors:  M A Pelosi; M A Pelosi
Journal:  JSLS       Date:  1997 Jul-Sep       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.